After 9 cycles of AZA, patient #23 was sensitive to AZA, had 12% blasts (RAEB-II in the MDS classification) and 40% BCL2L10 positive cells (Figure S2A). The gene discussed is BCL2L10; the disease is myelodysplastic syndrome.